Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8406MR)

This product GTTS-WQ8406MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8406MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13308MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ2484MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ7932MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ6726MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ7544MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ8640MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ10286MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ1686MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACZ885
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW